J8611 Oral methotrexate (jylamvo)
Also known as: Jylamvo, Methotrexate Jylamvo
Methotrexate (Jylamvo brand) administered orally; a folate antagonist antimetabolite for malignancies and autoimmune diseases.
In Plain Language
Cancer treatment pill; Autoimmune disease medication
Clinical Context
Jylamvo is a branded liquid formulation of methotrexate used for leukemia and autoimmune conditions. Provides flexible dosing.
RVU Information
CPT J8611 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J8611?
CPT J8611 (Oral methotrexate (jylamvo)) is a J Codes (Drugs) code. Methotrexate (Jylamvo brand) administered orally; a folate antagonist antimetabolite for malignancies and autoimmune diseases.
How is J8611 administered?
CPT J8611 is administered by a healthcare provider, typically via injection or infusion. Jylamvo is a branded liquid formulation of methotrexate used for leukemia and autoimmune conditions. Provides flexible dosing. It is used by Oncology, Rheumatology, Internal Medicine.
When is CPT J8611 used?
Jylamvo is a branded liquid formulation of methotrexate used for leukemia and autoimmune conditions. Provides flexible dosing.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.